Ari Maizel, Chief Commercial Officer at Axsome Therapeutics, Inc. (AXSM), sold 7,500 shares at $182.42 ($1.4M) on 2026-04-22, disclosed to the SEC on 2026-04-23.
Scheduled sale ($1.4M) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.